# **PRODUCT** INFORMATION



MI-2 (hydrochloride)

Item No. 11620

Formal Name:	4-(4-(5,5-dimethyl-4,5-dihydrothiazol-2- yl)piperazin-1-yl)-6-propylthieno[2,3-d]	N S
	pyrimidine, dihydrochloride	Ý '
MF:	$C_{18}H_{25}N_5S_2 \bullet 2HCI$	_N_
FW:	448.5	• 2HCl
Purity:	≥98%	N
UV/Vis.:	λ <sub>max</sub> : 224, 284 nm	Ļ
Supplied as:	A crystalline solid	s N
Storage:	-20°C	
Stability:	≥4 years	
Information represents the product excelling Datch excelling reputied reputed on each continents of		

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

## Laboratory Procedures

MI-2 (hydrochloride) is supplied as a crystalline solid. A stock solution may be made by dissolving the MI-2 (hydrochloride) in the solvent of choice, which should be purged with an inert gas. MI-2 (hydrochloride) is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide. The solubility of MI-2 (hydrochloride) in these solvents is approximately 30, 10, and 20 mg/ml, respectively.

## Description

Menin, a product of the multiple endocrine neoplasia gene, is an essential component of histone methyltransferase complexes involving the mixed lineage leukemia (MLL) gene product.<sup>1,2</sup> Also, the leukemogenic activity of MLL fusion proteins depends on their direct interaction with menin.<sup>3</sup> MI-2 potently binds menin, blocks the menin-MLL fusion protein interaction (IC<sub>50</sub> = 0.45  $\mu$ M), and induces apoptosis in cells expressing MLL fusion proteins.<sup>3</sup> Its actions can be compared with those of MI-nc (Item No. 11621), a weak inhibitor of the menin MLL interaction (IC<sub>50</sub> = 193  $\mu$ M).<sup>3</sup>

## References

- 1. Chandrasekharappa, S.C., Guru, S.C., Manickam, P., et al. Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science 276(5311), 404-407 (1997).
- 2. Guccione, E., Bassi, C., Casadio, F., et al. Methylation of histone H3R2 by PRMT6 and H3K4 by an MLL complex are mutually exclusive. Nature 449(7164), 933-937 (2007).
- 3. Grembecka, J., He, S., Shi, A., et al. Menin-MLL inhibitors reverse oncogenic activity of MLL fusion proteins in leukemia. Nat. Chem. Biol. 8(3), 277-284 (2012).

WARNING THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

### SAFFTY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

## WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 02/22/2024

# CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD ANN ARBOR, MI 48108 · USA PHONE: [800] 364-9897 [734] 971-3335 FAX: [734] 971-3640 CUSTSERV@CAYMANCHEM.COM WWW.CAYMANCHEM.COM